Headshot of David Meiri

David (Dedi) Meiri, PhD
Associate Professor
Head, Laboratory of Cancer Biology &
Cannabinoid Research - Technion
ADVISORY BOARD MEMBER
SPEAKER
SCIENCE

Cannabis as a Therapy Across Diverse Cancer Types: Milestones and Insights from a Decade of Research

For many years, Cannabis has been widely used in various countries as palliative and complementary treatment, providing therapeutic support alongside conventional medical interventions for a range of conditions. Over the past decade, my lab has focused on investigating whether Cannabis can serve as a primary pharmaceutical treatment for cancer and other diseases, beyond its traditional supportive roles.

Our journey began with the understanding that Cannabis is not a single drug but a versatile plant with multifaceted therapeutic effects, extending far beyond the actions of any single cannabinoid. With that we published our first paper “The heterogeneity and complexity of Cannabis extracts as antitumor agents”, which reflected how specific Cannabis extracts can impair cancer cell survival and proliferation and induce apoptosis, but their effects are highly variable, depending both on the extract’s composition and on the unique characteristics of the cancer cells.

From that point, we began cracking down on the specific and accurate combinations of molecules that target particular cancer types. We learned that sometimes a distinct combination of metabolites is required, while other times a rare cannabinoid is the underlying cause for the observed effects. At times, the metabolites affect the cancer cells directly and at times they interact with other cells and indirectly affect the cancer cells, for example immune cells in the tumor microenvironment. In such cases, Cannabis molecules can be ombined with immunotherapy to enhance its efficacy. Similarly, these molecules can be combined with chemotherapy to overcome multidrug resistance by modulating efflux pumps, enhancing drug retention in cancer cells.

Our decade-long research has shown that Cannabis, with its complex and diverse composition, holds great promise as treatment for cancer. By identifying precise combinations of cannabinoids and metabolites, we are exploring how Cannabis can enhance the efficacy of conventional therapies like chemotherapy and immunotherapy, providing a novel approach to combating cancer.

BIO

Associate Professor David (Dedi) Meiri heads the Laboratory of Cancer Biology and Cannabinoid Research at the Faculty of Biology in the Technion. Dr. Meiri comes from a highly diverse scientific background in biochemistry, plant biotechnology and cancer.

The research conducted in Dr. Meiri’s lab sets out to bridge the gap between herbal and modern medicine. The lab investigates the vast therapeutic potential of secondary metabolites from cannabis and other herbs, algae and psychedelic mushrooms; and reveals how these naturally occurring metabolites affect various types of cancer, inflammatory diseases and disorders of the nervous system such as epilepsy, Alzheimer’s and others. The lab consists of a highly trained team of skilled professionals and students, working in synergy to achieve the highest level of results, to better understand the complexity and diversity of cannabis and other natural components, and realize their full therapeutic potential for human health.

Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees that seek to advance the fundamental understanding of optimal cannabis and other psychedelic plants usage and curtailing adverse effects.

View CannMed Resources Below:

ATTENDANCE IS LIMITED. THE OPPORTUNITIES ARE NOT.

Image